These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 16447184)

  • 1. Kinetics of hepatitis C virus reinfection after liver transplantation.
    Powers KA; Ribeiro RM; Patel K; Pianko S; Nyberg L; Pockros P; Conrad AJ; McHutchison J; Perelson AS
    Liver Transpl; 2006 Feb; 12(2):207-16. PubMed ID: 16447184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.
    Russelli G; Pizzillo P; Iannolo G; Barbera F; Tuzzolino F; Liotta R; Traina M; Vizzini G; Gridelli B; Badami E; Conaldi PG
    PLoS One; 2017; 12(7):e0181683. PubMed ID: 28750044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance.
    Shekhtman L; Navasa M; Sansone N; Crespo G; Subramanya G; Chung TL; Cardozo-Ojeda EF; Pérez-Del-Pulgar S; Perelson AS; Cotler SJ; Forns X; Uprichard SL; Dahari H
    Elife; 2021 Nov; 10():. PubMed ID: 34730511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.
    Hughes MG; Tucker WW; Reddy S; Brier ME; Koch D; McClain CJ; Jonsson CB; Matoba N; Chung D
    PLoS One; 2017; 12(7):e0180719. PubMed ID: 28732019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of new treatment options for hepatitis C virus infection in liver transplantation.
    Righi E; Londero A; Carnelutti A; Baccarani U; Bassetti M
    World J Gastroenterol; 2015 Oct; 21(38):10760-75. PubMed ID: 26478668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.
    Rowe IA; Tully DC; Armstrong MJ; Parker R; Guo K; Barton D; Morse GD; Venuto CS; Ogilvie CB; Hedegaard DL; McKelvy JF; Wong-Staal F; Allen TM; Balfe P; McKeating JA; Mutimer DJ
    Liver Transpl; 2016 Mar; 22(3):287-97. PubMed ID: 26437376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatiotemporal analysis of hepatitis C virus infection.
    Shulla A; Randall G
    PLoS Pathog; 2015 Mar; 11(3):e1004758. PubMed ID: 25822891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
    Grassi A; Ballardini G
    World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing reveals large connected networks of intra-host HCV variants.
    Campo DS; Dimitrova Z; Yamasaki L; Skums P; Lau DT; Vaughan G; Forbi JC; Teo CG; Khudyakov Y
    BMC Genomics; 2014; 15 Suppl 5(Suppl 5):S4. PubMed ID: 25081811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.
    Babcock GJ; Iyer S; Smith HL; Wang Y; Rowley K; Ambrosino DM; Zamore PD; Pierce BG; Molrine DC; Weng Z
    PLoS One; 2014; 9(6):e100325. PubMed ID: 24956119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C.
    Harada N; Tamura S; Sugawara Y; Togashi J; Ishizawa T; Kaneko J; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Yamashiki N; Kokudo N
    PLoS One; 2014; 9(3):e90462. PubMed ID: 24599320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle.
    Binder M; Sulaimanov N; Clausznitzer D; Schulze M; Hüber CM; Lenz SM; Schlöder JP; Trippler M; Bartenschlager R; Lohmann V; Kaderali L
    PLoS Pathog; 2013; 9(8):e1003561. PubMed ID: 23990783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.
    Russo MW; Narang T; Eskind L; Hayes D; Casingal V; Purdum PP; Hanson JS; Ahrens W; Norton J; Bonkovsky H
    Dig Dis Sci; 2013 Oct; 58(10):3010-6. PubMed ID: 23812862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights in recurrent HCV infection after liver transplantation.
    Hsu SH; Yeh ML; Wang SN
    Clin Dev Immunol; 2013; 2013():890517. PubMed ID: 23710205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.
    Rong L; Guedj J; Dahari H; Coffield DJ; Levi M; Smith P; Perelson AS
    PLoS Comput Biol; 2013; 9(3):e1002959. PubMed ID: 23516348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
    Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.
    Chung RT; Gordon FD; Curry MP; Schiano TD; Emre S; Corey K; Markmann JF; Hertl M; Pomposelli JJ; Pomfret EA; Florman S; Schilsky M; Broering TJ; Finberg RW; Szabo G; Zamore PD; Khettry U; Babcock GJ; Ambrosino DM; Leav B; Leney M; Smith HL; Molrine DC
    Am J Transplant; 2013 Apr; 13(4):1047-1054. PubMed ID: 23356386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected maintenance of hepatitis C viral diversity following liver transplantation.
    Gray RR; Strickland SL; Veras NM; Goodenow MM; Pybus OG; Lemon SM; Fried MW; Nelson DR; Salemi M
    J Virol; 2012 Aug; 86(16):8432-9. PubMed ID: 22623804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal bioartificial liver for treating acute liver diseases.
    Kumar A; Tripathi A; Jain S
    J Extra Corpor Technol; 2011 Dec; 43(4):195-206. PubMed ID: 22416599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approach for quantification of hepatitis C virus in liver cirrhosis using real-time reverse transcriptase PCR.
    Maudar KK; Gandhi P; Mishra PK; Varshney S; Punde R; Bhargav A
    J Gastrointest Surg; 2012 Jan; 16(1):142-6; discussion 146-7. PubMed ID: 22048842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.